All In Biotech

Drug Trial Radar · NCT06444529

A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness

A Double-Masked Comparison of Apraclonidine Hydrochloride Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Aug 21, 2024

Primary completion

Nov 14, 2024

Study completion Jan 8, 2025

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Jun 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle in relieving redness of the eye due to minor eye irritations. This study will be conducted in the United States.

Conditions

  • Ocular Redness

Interventions

  • Apraclonidine Hydrochloride Ophthalmic SolutionDrug

    Investigational ophthalmic solution applied topically to the eye with a dropper bottle

  • VehicleDrug

    Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Squares Mean Change From Baseline in Investigator-Assessed Ocular Redness at 15 Minutes Post-instillation on Day 1Time frame: Baseline (Day 1 pre-instillation); Minute 15 (Day 1 post-instillation)
  2. Least Squares Mean Change From Baseline in Investigator-assessed Ocular Redness at 10 Hours (600 Minutes) Post-instillation on Day 1Time frame: Baseline (Day 1 pre-instillation); Hour 10 (600 minutes) (Day 1 post-instillation)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Global Research Management

    Glendale, California

  • Oculus Research, Inc.

    Garner, North Carolina

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania

  • Emerson Clinical Research Institute, Inc.

    Falls Church, Virginia

  • Piedmont Eye Center

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.